Literature DB >> 9094984

Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.

S M Wahl1, P Worley, W Jin, T B McNeely, S Eisenberg, C Fasching, J M Orenstein, E N Janoff.   

Abstract

The rarity of oral transmission of human immunodeficiency virus (HIV)-1 by saliva suggests the absence of HIV-1 in the oral cavity and/or the presence of viral inhibitory molecules. We analyzed salivary gland tissues from 55 individuals with acquired immune deficiency syndrome (AIDS) for the presence of HIV-1 by in situ hybridization and detected the virus in more than 30% of these salivary glands. These data, together with previous demonstrations of HIV-1 in oral secretions, implicate a key role for an anti-viral molecule(s) in suppressing transmission. Thus, we focused on the characterization and localization of the endogenous antiviral molecule secretory leukocyte protease inhibitor (SLPI), which inhibits HIV-1 infection in vitro. Expression of SLPI transcripts was evident in submandibular, parotid, and minor salivary glands from both HIV-1-infected and seronegative subjects. Gene expression was reflected by similar levels of SLPI protein by immunohistochemical analysis in the tissues and by enzyme-linked immunosorbent assay in the saliva. However, although SLPI accumulated in acinar cells or ductal epithelium, HIV-1 transcripts did not, and these viral transcripts were identified only in mononuclear cells within the salivary gland stroma. By in situ hybridization, we found no evidence of productive HIV-1 infection of salivary gland epithelium. Thus, HIV-1 was frequently identified in salivary gland tissue, but the virus was found in interstitial mononuclear cells only and did not co-localize with SLPI. Once within the oral cavity, HIV-1 exposure to antiviral levels of SLPI may impede infection of additional target cells, contributing to the virtual absence of oral transmission of HIV-1 by saliva. These studies emphasize the importance of innate, endogenous inhibitors of HIV-1, particularly SLPI, as effective inhibitors of HIV-1 transmission.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094984      PMCID: PMC1858155     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  AIDS-associated infections in salivary glands: autopsy survey of 60 cases.

Authors:  R P Wagner; H Tian; M J McPherson; P S Latham; J M Orenstein
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

2.  Infrequency of isolation of HTLV-III virus from saliva in AIDS.

Authors:  D D Ho; R E Byington; R T Schooley; T Flynn; T R Rota; M S Hirsch
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

3.  The origin and variation in number of leukocytes in the human saliva.

Authors:  C R Schiött; H Löe
Journal:  J Periodontal Res       Date:  1970       Impact factor: 4.419

4.  Components of saliva inactivate human immunodeficiency virus.

Authors:  P N Fultz
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

5.  Studies on the role of antileukoprotease in respiratory tract diseases.

Authors:  U Fryksmark; T Prellner; H Tegner; K Ohlsson
Journal:  Eur J Respir Dis       Date:  1984-04

6.  Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis.

Authors:  L M Wahl; I M Katona; R L Wilder; C C Winter; B Haraoui; I Scher; S M Wahl
Journal:  Cell Immunol       Date:  1984-05       Impact factor: 4.868

7.  Localization of antileukoprotease in the parotid and the submandibular salivary glands.

Authors:  M Ohlsson; U Fryksmark; A Polling; H Tegner; K Ohlsson
Journal:  Acta Otolaryngol       Date:  1984 Jul-Aug       Impact factor: 1.494

8.  HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS.

Authors:  J E Groopman; S Z Salahuddin; M G Sarngadharan; P D Markham; M Gonda; A Sliski; R C Gallo
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

9.  Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase.

Authors:  R C Thompson; K Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

10.  Localization of low molecular weight protease inhibitor in serous secretory cells of the respiratory tract.

Authors:  J A Kramps; C Franken; C J Meijer; J H Dijkman
Journal:  J Histochem Cytochem       Date:  1981-06       Impact factor: 2.479

View more
  12 in total

Review 1.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

2.  Characterization of human immunodeficiency virus type 1 in saliva and blood plasma by V3-specific heteroduplex tracking assay and genotype analyses.

Authors:  S A Freel; J M Williams; J A Nelson; L L Patton; S A Fiscus; R Swanstrom; D C Shugars
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers.

Authors:  H Hocini; P Becquart; H Bouhlal; H Adle-Biassette; M D Kazatchkine; L Bélec
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

4.  Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.

Authors:  N K Jana; L R Gray; D C Shugars
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 5.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

6.  Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action.

Authors:  Raina N Fichorova; Hidemi S Yamamoto; Mary L Delaney; Andrew B Onderdonk; Gustavo F Doncel
Journal:  MBio       Date:  2011-10-25       Impact factor: 7.867

7.  The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay.

Authors:  Habtom H Habte; Anwar S Mall; Corena de Beer; Zoë E Lotz; Delawir Kahn
Journal:  Virol J       Date:  2006-11-24       Impact factor: 4.099

8.  Estimation and comparison of salivary secretory leukocyte protease inhibitor in human immunodeficiency virus patients and healthy individuals.

Authors:  Kumar Pushpanshu; Ramhari S Sathawane; Rachna Kaushik
Journal:  Indian J Palliat Care       Date:  2014-01

9.  Stone age diseases and modern AIDS.

Authors:  Arthur L Koch
Journal:  Virol J       Date:  2008-08-07       Impact factor: 4.099

10.  Salivary mucins in host defense and disease prevention.

Authors:  Erica Shapiro Frenkel; Katharina Ribbeck
Journal:  J Oral Microbiol       Date:  2015-12-22       Impact factor: 5.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.